Plain-English translation of NCT06265025 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing a new cancer treatment called GM103 that is injected directly into tumors. The study will test whether GM103 works better on its own or when combined with pembrolizumab, an immunotherapy medication that helps your immune system fight cancer. Researchers want to find the right dose and understand how safe and effective this treatment is for people with advanced cancers that have not responded well to standard therapies.
Current treatments don't work well enough for some people with advanced cancers, especially tumors that cannot be surgically removed. This medication is designed to work directly within the tumor to trigger the body's immune system to attack cancer cells, offering a potentially new option for patients who need better treatment choices.
You likely qualify if…
You likely don't qualify if…
You will visit the clinic regularly for the study team to inject the medication directly into your tumor. Depending on which part of the trial you join, you may receive the medication alone or combined with pembrolizumab infusions. You will have frequent imaging scans and blood tests to monitor how your cancer responds and watch for side effects. Some participants will also need to undergo tumor biopsies before and during treatment to help researchers understand how the medication is working.
AI-generated summary from trial data · Jul 15, 2026 · Not medical advice
South Korea